What is PEA (Palmitoylethanolamide) ?
Palmitoylethanolamide (PEA) is an endocannabinoid-like lipid mediator that has been gaining increasing attention in the management of pain and inflammation. First isolated in the 1950s as an anti-viral agent, PEA was later recognized for its potent analgesic and anti-inflammatory properties. Today, it is available in Europe as a “Food for Special Medical Purposes” and more recently as a dietary supplement across the globe. Research now positions PEA as a safe and promising adjunctive therapy for chronic pain and related conditions.
Poster Presented at Painweek September 4, 2025 Las Vegas, Nevada
A promising early signal for complex migraine support
In a carefully documented, 30-day clinical case, use of ultra-micronized PEA with organic curcumin and ginger (Migra-Well EZ Soothe & Revive) coincided with meaningful changes in migraine disability, headache frequency, pain intensity, and selected inflammatory markers.
PAINWEEK 2026 • ACCEPTED CASE REPORT
The 2026 Long COVID Case
A complex history. A clearly documented observation.
A 19-year-old with migraine since childhood developed chronic migraine, severe brain fog, and nausea following recurrent COVID-19. After nearly a year of persistent symptoms and multiple prior treatments, a clinician-directed trial of Migra Well ez Soothe & Revive was started.
Before treatment
Chronic migraine reported at 15–25 days per month, with brain fog and nausea affecting daily function.
01
Clinician-directed trial
Migra Well ez Soothe & Revive was added using an individualized schedule. No other treatment-course changes during the 30-day observation.
02
Day 30 follow-up
Disability, weekly migraine frequency, pain intensity, and a panel of inflammatory markers were measured again.
03
What was observed
The patient also reported improvement in fatigue and brain fog and was able to return to normal activity.
The case also followed inflammatory markers.
EXPLORATORY LABORATORY OBSERVATIONS
All markers presented in the Painweek 2026 poster decreased numerically over 30 days.
Read these results in context.
This was one exploratory case study, not a randomized trial. It documents an association and cannot show that the product caused the changes or that others should expect similar results.
STUDY AUTHOR & CLINICAL ADVISOR
Robert A. Bonakdar, MD, FAAFP, FACN
Director of Pain Management at Scripps Center for Integrative Medicine and an integrative pain and headache specialist.
Disclosure: Dr. Bonakdar serves as a consultant to Wellkasa. The 2026 poster was co-authored with Megan Sweeney, MPH.
Follow the evidence
2025
PEA in migraine, neuropathy, fibromyalgia, and musculoskeletal pain
A review of PEA mechanisms and human research across several chronic pain conditions.
2026
PEA, ginger, and curcumin in a complex migraine case.
A 30-day exploratory case report documenting disability, migraine frequency, pain intensity, function, and laboratory markers.
Disclosure: Dr. Bonakdar serves as a consultant to Wellkasa. The 2026 poster was co-authored with Megan Sweeney, MPH.
Request a complimentary clinician sample.
FOR HEALTHCARE PROFESSIONALS ONLY
Submit your professional information.
After verification, we will email you a free redemption to link for Migra Well ez Soothe & Revive.